201 related articles for article (PubMed ID: 10631192)
1. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.
Robbins IM; Gaine SP; Schilz R; Tapson VF; Rubin LJ; Loyd JE
Chest; 2000 Jan; 117(1):14-8. PubMed ID: 10631192
[TBL] [Abstract][Full Text] [Related]
2. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment.
Fisher KA; Serlin DM; Wilson KC; Walter RE; Berman JS; Farber HW
Chest; 2006 Nov; 130(5):1481-8. PubMed ID: 17099027
[TBL] [Abstract][Full Text] [Related]
3. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
4. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
5. Successful Management of Pregnancy in a Patient with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension.
Kawabe A; Nakano K; Aiko Y; Aramaki S; Onoue T; Okura D; Tanaka Y
Intern Med; 2018 Jun; 57(11):1655-1659. PubMed ID: 29321410
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
7. Epoprostenol-induced pulmonary vasodilatation in patients with pulmonary hypertension measured by electrical impedance tomography.
Smit HJ; Vonk Noordegraaf A; Roeleveld RJ; Bronzwaer JG; Postmus PE; de Vries PM; Boonstra A
Physiol Meas; 2002 Feb; 23(1):237-43. PubMed ID: 11878269
[TBL] [Abstract][Full Text] [Related]
8. Intermittent epoprostenol infusions in systemic lupus erythematosus associated pulmonary hypertension--a series of three cases.
Kong KO; Badsha H; Thumboo J; Chng HH
Ann Acad Med Singap; 2003 Jan; 32(1):118-21. PubMed ID: 12625109
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of epoprostenol therapy in sarcoid associated pulmonary hypertension.
Abston E; Moll M; Hon S; Govender P; Berman J; Farber H
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):184-191. PubMed ID: 33093782
[TBL] [Abstract][Full Text] [Related]
10. Low-dose epoprostenol improved pulmonary hypertension in a patient with systemic lupus erythematosus.
Matsukawa Y; Igei K; Nozaki T; Ohki T; Shimizu T; Kitamura N; Mitamura K; Takei M; Kasamaki Y; Sawada S
Clin Rheumatol; 2007 Apr; 26(4):582-3. PubMed ID: 16391888
[TBL] [Abstract][Full Text] [Related]
11. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure.
Montalescot G; Drobinski G; Meurin P; Maclouf J; Sotirov I; Philippe F; Choussat R; Morin E; Thomas D
Am J Cardiol; 1998 Sep; 82(6):749-55. PubMed ID: 9761085
[TBL] [Abstract][Full Text] [Related]
12. Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center.
Shirai Y; Yasuoka H; Takeuchi T; Satoh T; Kuwana M
Mod Rheumatol; 2013 Nov; 23(6):1211-20. PubMed ID: 23359006
[TBL] [Abstract][Full Text] [Related]
13. Successful transition from intravenous epoprostenol to oral selexipag and inhaled iloprost in a case of severe pulmonary arterial hypertension associated with systemic lupus erythematosus.
Saiki C; Kashiwado Y; Yokoyama T; Ayano M; Imabayashi K; Kawano S; Higashioka K; Kimoto Y; Fukata M; Mitoma H; Ono N; Arinobu Y; Akashi K; Horiuchi T; Niiro H
Mod Rheumatol Case Rep; 2022 Jun; 6(2):183-188. PubMed ID: 35134204
[TBL] [Abstract][Full Text] [Related]
14. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.
McLaughlin VV; Genthner DE; Panella MM; Hess DM; Rich S
Ann Intern Med; 1999 May; 130(9):740-3. PubMed ID: 10357693
[TBL] [Abstract][Full Text] [Related]
15. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension.
Strange C; Bolster M; Mazur J; Taylor M; Gossage JR; Silver R
Chest; 2000 Oct; 118(4):1077-82. PubMed ID: 11035680
[TBL] [Abstract][Full Text] [Related]
16. [Systemic lupus erythematosus with pulmonary hypertension--normalization of pulmonary artery pressure by long-term administration of beraprost sodium].
Ubukata M; Motegi M; Sendo Y; Suzuki T
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Nov; 33(11):1307-12. PubMed ID: 8583727
[TBL] [Abstract][Full Text] [Related]
17. Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension.
Schenk P; Petkov V; Madl C; Kramer L; Kneussl M; Ziesche R; Lang I
Chest; 2001 Jan; 119(1):296-300. PubMed ID: 11157622
[TBL] [Abstract][Full Text] [Related]
18. Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol.
Rafanan AL; Maurer J; Mehta AC; Schilz R
Chest; 2000 Nov; 118(5):1497-500. PubMed ID: 11083710
[TBL] [Abstract][Full Text] [Related]
19. Severe pulmonary hypertension in a patient with systemic lupus erythematosus and minimal lupus activity.
Kawamura N; Tsutsui H; Fukuyama K; Hayashidani S; Koike G; Egashira K; Abe Y; Yamamoto H; Tsuneyoshi M; Takeshita A
Intern Med; 2002 Feb; 41(2):109-12. PubMed ID: 11868596
[TBL] [Abstract][Full Text] [Related]
20. Use of aerosolized inhaled epoprostenol in the treatment of portopulmonary hypertension.
Schroeder RA; Rafii AA; Plotkin JS; Johnson LB; Rustgi VK; Kuo PC
Transplantation; 2000 Aug; 70(3):548-50. PubMed ID: 10949204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
